SurModics and X-Cell Medical form drug-eluting stent polymer matrix licensing pact:
This article was originally published in Clinica
Executive Summary
SurModics and X-Cell Medical have formed a licensing deal to use SurModics' Bravo drug delivery polymer matrix with X-Cell's Ethos drug-eluting stent (DES) for coronary use. SurModics' Bravo will be used to deliver 17 beta-oestradiol - an agent thought to reduce in-stent restenosis by suppressing neointimal hyperplasia. In addition, Princeton, New Jersey-based X-cell has completed enrolment in its ETHOS I and II clinical trials and has reported zero incidence of thrombosis thus far. SurModics, based in Eden Prairie, Minnesota has licensing agreements with seven other DES-makers.